Volume 9, Issue 3 (7-2023)
Journal of Research in Applied and Basic Medical Sciences 2023, 9(3): 183-192 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
M P K R, Fatima R, Karamchedu S, Punjala M G, Patale V, K F N et al . Study of gastrointestinal neoplasms, histopathologic and immunohistochemical correlation using HER-2/NEU, CK-7 and CK-20. Journal of Research in Applied and Basic Medical Sciences 2023; 9 (3) :183-192
URL: http://ijrabms.umsu.ac.ir/article-1-255-en.html
URL: http://ijrabms.umsu.ac.ir/article-1-255-en.html
Pramod Kumar Reddy M 
, Rasheed Fatima * , Shilpa Karamchedu , Manisha Goud Punjala , Vishali Patale , Florence N K , Suresh K
, Rasheed Fatima * , Shilpa Karamchedu , Manisha Goud Punjala , Vishali Patale , Florence N K , Suresh K
Professor, Department of Pathology, SVS Medical College and Hospital, Yenugonda, Mahabubnagar, Telangana-509001, India. , drrasheedfatima786@gmail.com
Abstract: (661 Views)
Background & Aims: This study aimed to determine the significance of immunohistochemistry (IHC) and its correlation using HER-2/NEU and cytokeratins in a histopathologic study of GI neoplasms.
Materials & Methods: This retrospective- prospective study was conducted on 50 gastric biopsies along with patient details and stained with H and E method for histopathology. Immunohistochemistry with HER-2/NEU, cytokeratin-7 and cytokeratin-20 were also done.
Results: 60% were males among total sample size. Adenocarcinoma prevalence was 76%, followed by mucinous adenocarcinoma in 10%, signet cell ring cell carcinoma in 6%, and mixed adeno-neuroendocrine tumor in 4%. Sarcoma and papillary adenocarcinoma contributed to 2% each. Among study population, 60% were of grade II, 32% were of grade III, and 6% were of grade I. Low-grade sarcoma was present in 2%. Well differentiated tumors were 6%, moderately differentiated tumors were 60%, and poorly differentiated tumors were 32%. Among study population, 16% were positive for Her 2 neu, 20% were positive for CK7, and CK20 was positive in 28%, respectively. Among the study population, 2.63% of adenocarcinomas, all of mixed adeno-neuroendocrine, 60% of mucinous adenocarcinomas, and 66.66% of signet ring cell carcinomas were positive for Her2neu. 18.42% of adenocarcinomas, 50% of mixed adeno-neuroendocrine and 66.66% of signet ring cell carcinomas were positive for CK7. 21.05% of adenocarcinomas, all of mucinous adenocarcinomas, and 33.33% of signet ring cell carcinomas were positive for CK20.
Conclusion: 16% were positive for Her 2 neu, 20% were positive for CK7, and CK20 was positive among 28%. There was no correlation between the histopathology status and receptor positivity.
Materials & Methods: This retrospective- prospective study was conducted on 50 gastric biopsies along with patient details and stained with H and E method for histopathology. Immunohistochemistry with HER-2/NEU, cytokeratin-7 and cytokeratin-20 were also done.
Results: 60% were males among total sample size. Adenocarcinoma prevalence was 76%, followed by mucinous adenocarcinoma in 10%, signet cell ring cell carcinoma in 6%, and mixed adeno-neuroendocrine tumor in 4%. Sarcoma and papillary adenocarcinoma contributed to 2% each. Among study population, 60% were of grade II, 32% were of grade III, and 6% were of grade I. Low-grade sarcoma was present in 2%. Well differentiated tumors were 6%, moderately differentiated tumors were 60%, and poorly differentiated tumors were 32%. Among study population, 16% were positive for Her 2 neu, 20% were positive for CK7, and CK20 was positive in 28%, respectively. Among the study population, 2.63% of adenocarcinomas, all of mixed adeno-neuroendocrine, 60% of mucinous adenocarcinomas, and 66.66% of signet ring cell carcinomas were positive for Her2neu. 18.42% of adenocarcinomas, 50% of mixed adeno-neuroendocrine and 66.66% of signet ring cell carcinomas were positive for CK7. 21.05% of adenocarcinomas, all of mucinous adenocarcinomas, and 33.33% of signet ring cell carcinomas were positive for CK20.
Conclusion: 16% were positive for Her 2 neu, 20% were positive for CK7, and CK20 was positive among 28%. There was no correlation between the histopathology status and receptor positivity.
Type of Study: orginal article |
Subject:
Other
References
1. Stewart BW, Wild CP, editors. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer; 2014 [URL]
2. Dikshit R, Gupta PC, Ramasundarahettige C, Gajalakshmi V, Aleksandrowicz L, Badwe R, et al. Cancer mortality in India: A nationally representative survey. Lancet 2012;379:1807-16.
https://doi.org/10.1016/S0140-6736(12)60358-4 [DOI:10.1016/s0140-6736(12)60358-4] [PMID]
3. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144:1941-53. [DOI:10.1002/ijc.31937] [PMID]
4. Wang HB, Liao XF, Zhang J. Clinicopathological factors associated with HER2- positive gastric cancer: A meta-analysis. Medicine (Baltimore) 2017;96:e8437.
https://doi.org/10.1097/MD.0000000000008437 [DOI:10.1097/md.0000000000008437] [PMID] []
5. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology 2008;52:797-805. [DOI:10.1111/j.1365-2559.2008.03028.x] [PMID]
6. Mabula JB, McHembe MD, Koy M, Chalya PL, Massaga F, Rambau PF, et al. Gastric cancer at a university teaching hospital in northwestern Tanzania: A retrospective review of 232 cases. World J Surg Oncol 2012;10:257. [DOI:10.1186/1477-7819-10-257] [PMID] []
7. Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer 2004;108:540-8. [DOI:10.1002/ijc.11599] [PMID]
8. Jindal Y, Varma K, Misra V, Kumar R, Singh A, Misra SP, et al. Cytoplasmic expression of HER2 in gastric adenocarcinoma: An unusual finding. Indian J Med Res Pharm Sci 2016;3. [Google Scholar]
9. Hernandez BY, Frierson HF, Moskaluk CA, Li YJ, Clegg L, Cote TR, McCusker ME, Hankey BF, Edwards BK, Goodman MT: CK20 and CK7 protein expression in colorectal carcinoma: demonstration of the utility of a population-based tissue microarray. Hum Pathol 2005;36:275-81. [DOI:10.1016/j.humpath.2005.01.013] [PMID]
10. Zhang PJ, Shah M, Spiegel GW, Brooks JJ: Cytokeratin 7 immunoreactivity in rectal adenocarcinomas. Appl Immunohistochem Mol Morphol 2003;11:306-10. [DOI:10.1097/00129039-200312000-00005] [PMID]
11. Park SY, Kim HS, Hong EK, Kim WH: Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum andt heirvalue in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 2002;33:1078-85. [DOI:10.1053/hupa.2002.129422] [PMID]
12. Rullier A, Le Bail B, Fawaz R, Blanc JF, Saric J, Bioulac-Sage P: Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but stil differs from that in colorectal carcinomas metastasis. Am J Surg Pathol 2000;24:870-6. [DOI:10.1097/00000478-200006000-00014] [PMID]
13. Drummond F, Putt W, Fox M, Edwards YH: Cloning and chromosome assignment of the human CDX2 gene. Ann Hum Genet 1997;393-400.
https://doi.org/10.1017/S0003480097006465 [DOI:10.1017/s0003480097006465] [PMID]
14. Parmar A, Kokani M. J, Patel M. A study of neoplast ic study of gastrointestinal tumors. Trop J Path Micro 2018;4(1):27-33. [DOI:10.17511/jopm.2018.i01.05]
15. Mahajan, Mahajan NA, Kale SS, Bhale CP. Histopathology of Gastrointestinal Tract Malignancies - A Two Year Retrospective Study. Annals of Pathology and Laboratory Medicine, Vol. 4, Issue 4, July-August, 2017
https://doi.org/10.21276/APALM.1246 [DOI:10.21276/apalm.1246]
16. Pandey I, Misra V, Pandey AT, Verma A. Expression of HER2/neu in gastric adenocarcinoma and its correlation with serum HER2/neu level and E-cadherin expression. Indian J Pathol Microbiol 2022;65:35-41. [Google Scholar]
17. Jeong O, Park YK. Clinicopathological features and surgical treatment of gastric cancer in South Korea: The results of 2009 nationwide survey on surgically treated gastric cancer patients. J Gastric Cancer 2011;11:69-77. [DOI:10.5230/jgc.2011.11.2.69] [PMID] []
18. Gill MK, Jain K, Manjari M, Kaur T. Expression of Her-2/neu in colon carcinoma and its correlation with the histological grades and the lymph nodes status. J Clin Diagn Res 2011;5:1564-8. [Google Scholar]
19. Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Mol Biol Int 2014;2014:852748 [DOI:10.1155/2014/852748] [PMID] []
20. Blok EJ, Kuppen PJ, van Leeuwen JE, Sier CF. Cytoplasmic overexpression of HER2: A key factor in colorectal cancer. Clin Med Insights Oncol 2013;7:41-51
https://doi.org/10.4137/CMO.S10811 [DOI:10.4137/cmo.s10811] [PMID] []
21. Chu P, Wu E, Weiss, L. Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases. Mod Pathol 2000.13, 962-972. [DOI:10.1038/modpathol.3880175] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Contact Information
Address: Urmia University of Medical Sciences, Jahad Ave., Urmia, I.R. Iran. Post code: 57147-83734. P.O. Box. 1138
Email: ijrabms
gmail.com
rabmsumsu.ac.ir
Tel / Fax: +984431937332/+984432240642
